RESEARCH ON TOPICAL GEL CONTAINING SOLID LIPID NANOPARTICLES LOADED WITH ACYCLOVIR

For extended therapeutic effect in the treatment of viral infections, new topical pharmacological alternatives are urgently required. In order to produce an efficient topical Acyclovir solid lipid nanoparticles (SLN) gel formulation with long-term therapeutic potential against tropical viral infections, bioavailability hurdles of Acyclovir were overcome. Acyclovir is a topical antiviral medication used to treat viral infections. Stearic acid and poloxamer 188 were used in the solvent diffusion approach to create the SLN for acyclovir. For the leading moiety’s veracity, preformulation investigations were carried out. The generated SLN and gel formulations were then put through physicochemical testing, in-vitro drug release profiles, and kinetics studies. Following that, successful FTIR spectroscopy and scanning electron microscopy of the improved formulation were performed. The findings suggest that SLN F6 has a strong entrapment efficacy, with the greatest entrapment of 92.13%0.975. In terms of particle size, size distribution, and zeta potential, SLN show a mean particle diameter of about 344.3 nm, a unimodal size distribution, a polydispersity index of 0.168, an intercept value of 0.98 with 92% peak intensity, and a zeta potential of around 18.8 mV. Moreover, compared to other formulations, G3 gel exhibits a greater entrapment efficacy of 91.39%0.187. The G3 gel with 1.5% carbopol 934 w/v exhibits a sustained drug release profile with 79.57%0.213 of the drug release even after 24 hours. It is concluded that the Acyclovir loaded SLN based gel formulation containing carbopol 934 1.5% w/v is suitable for topical application and may show a much better result of anti-viralactivity.